Delivery Order SPE2DR25D2104-SPE2DR26F3SGF
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,896.50 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 pods (Generation 5) with a 5-unit configuration. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for completion by December 3, 2025. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters as a major pharmaceutical...
- The Defense Logistics Agency awarded a $1,372.91 firm fixed price delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 generation 5 pods on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, non-set-aside contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under the company's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 pods (Generation 5) in the 5-pack configuration, valued at $4,407.61. This is a firm fixed-price delivery order with no set-aside designation, issued on June 18, 2025, with an ultimate completion date of June 20, 2025. AmerisourceBergen's corporate office, located in Conshohocken, Pennsylvania, will serve as the place of performance. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,603.61 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 continuous glucose monitoring system pods (Generation 5), with performance in Conshohocken, Pennsylvania. This is a firm fixed price, competitively awarded contract with an ultimate completion date of August 21, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as the prime contractor under this...
- The Defense Logistics Agency (DLA) awarded a $7,826.55 firm fixed-price delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 pods. The contract, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a non-competitive procurement of specialized diabetic medical devices. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and fulfills the delivery order through its corporate office division....
- The Defense Logistics Agency awarded a delivery order valued at $3,959.27 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. This competitively awarded, firm fixed-price contract has an ultimate completion date of August 26, 2025, and represents a non-set-aside procurement. The products will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $2,395.34 delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods. The contract, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a firm fixed price procurement with no set-aside designation. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this medical device delivery, which supports the federal government's...
- The Defense Logistics Agency awarded a $3,951.77 delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 pods (Generation 5), with a completion date of July 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a child order under AmerisourceBergen's larger contract vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $8,040.58 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods. The contract, which was competitively awarded without set-aside provisions, has a performance completion date of December 10, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $3,248.22 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 pods. Issued on December 22, 2025, with an ultimate completion date of December 23, 2025, this firm fixed price delivery order represents a competitively awarded, non-set-aside contract. The products will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- SPE2DR25D2104Indefinite Delivery Contract
- SPE2DR25D2104-SPE2DR26F3SGFDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,467.30 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 pods, with performance in Conshohocken, Pennsylvania and completion by December 26, 2025. This is a firm fixed price, non-set-aside contract that leverages AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The delivery order reflects DLA's medical supply chain procurement needs for diabetes management devices supporting military and federal healthcare beneficiaries. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement and holds significant contract portfolio with DLA covering pharmaceuticals, vaccines, and specialized medical supplies across multiple therapeutic domains. The company's federal awards demonstrate consistent capability to meet competitive procurement requirements through firm fixed pricing delivery orders of varying scales. This particular order for continuous glucose monitoring pods supports the broader DLA Pharmaceutical Prime Vendor Global Program initiative, which strategically engages multiple regional contractors to ensure comprehensive medical supply coverage for military healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 12/23/25 |